BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that the company has begun a multicenter Phase I pharmacologic clinical trial of CYC116, an orally-available inhibitor of Aurora kinases A and B, and VEGFR2, in patients with advanced solid tumors. The study will be conducted by Nithya Ramnath, M.D., Alex A. Adjei, M.D. and colleagues at Roswell Park Cancer Institute in Buffalo, New York, and Anthony Tolcher, M.D. and colleagues at South Texas Accelerated Research Therapeutics (START) in San Antonio, Texas. The study is the first of two clinical trials the company plans to begin this year to evaluate CYC116’s potential in solid and hematological tumors.
